DK0996444T3 - Behandling af diabetes med thiazolidindion og metformin - Google Patents

Behandling af diabetes med thiazolidindion og metformin

Info

Publication number
DK0996444T3
DK0996444T3 DK98936364T DK98936364T DK0996444T3 DK 0996444 T3 DK0996444 T3 DK 0996444T3 DK 98936364 T DK98936364 T DK 98936364T DK 98936364 T DK98936364 T DK 98936364T DK 0996444 T3 DK0996444 T3 DK 0996444T3
Authority
DK
Denmark
Prior art keywords
thiazolidinedione
metformin
diabetes
treatment
Prior art date
Application number
DK98936364T
Other languages
Danish (da)
English (en)
Inventor
Stephen Smith
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26311745&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0996444(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9712857.3A external-priority patent/GB9712857D0/en
Priority claimed from GBGB9806706.9A external-priority patent/GB9806706D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of DK0996444T3 publication Critical patent/DK0996444T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK98936364T 1997-06-18 1998-06-15 Behandling af diabetes med thiazolidindion og metformin DK0996444T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9712857.3A GB9712857D0 (en) 1997-06-18 1997-06-18 Novel method of treatment
GBGB9806706.9A GB9806706D0 (en) 1998-03-27 1998-03-27 Novel method
PCT/EP1998/003690 WO1998057634A1 (en) 1997-06-18 1998-06-15 Treatment of diabetes with thiazolidinedione and metformin

Publications (1)

Publication Number Publication Date
DK0996444T3 true DK0996444T3 (da) 2007-07-02

Family

ID=26311745

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98936364T DK0996444T3 (da) 1997-06-18 1998-06-15 Behandling af diabetes med thiazolidindion og metformin

Country Status (38)

Country Link
US (3) US20060100247A1 (en:Method)
EP (2) EP0996444B1 (en:Method)
JP (1) JP2002504137A (en:Method)
KR (2) KR100666591B1 (en:Method)
CN (2) CN1114404C (en:Method)
AP (1) AP1279A (en:Method)
AR (2) AR012998A1 (en:Method)
AT (1) ATE355840T1 (en:Method)
AU (1) AU8539398A (en:Method)
BG (2) BG109398A (en:Method)
BR (1) BR9810172A (en:Method)
CA (1) CA2294582C (en:Method)
CY (2) CY1107643T1 (en:Method)
CZ (1) CZ298469B6 (en:Method)
DE (2) DE69837261T2 (en:Method)
DK (1) DK0996444T3 (en:Method)
DZ (1) DZ2520A1 (en:Method)
EA (1) EA003144B1 (en:Method)
ES (1) ES2284212T3 (en:Method)
ID (1) ID23372A (en:Method)
IL (3) IL133142A0 (en:Method)
IN (1) IN189722B (en:Method)
LU (1) LU91356I2 (en:Method)
MA (1) MA26512A1 (en:Method)
MY (1) MY129897A (en:Method)
NL (1) NL300288I2 (en:Method)
NO (4) NO324993B1 (en:Method)
NZ (1) NZ501260A (en:Method)
OA (1) OA11516A (en:Method)
PE (1) PE83199A1 (en:Method)
PL (2) PL195136B1 (en:Method)
PT (1) PT996444E (en:Method)
SI (1) SI0996444T1 (en:Method)
SK (1) SK286029B6 (en:Method)
TR (1) TR199903057T2 (en:Method)
TW (1) TW565449B (en:Method)
UY (1) UY25049A1 (en:Method)
WO (1) WO1998057634A1 (en:Method)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2158607C2 (ru) * 1995-07-03 2000-11-10 Санкио Компани Лимитед Лечение артериосклероза и ксантомы
GB9712857D0 (en) * 1997-06-18 1997-08-20 Smithkline Beecham Plc Novel method of treatment
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
ES2206868T3 (es) * 1998-07-15 2004-05-16 Merck Sante Comprimidos que comprenden una combinacion de metformin glibenclamida.
AU3960400A (en) * 1999-03-05 2000-09-28 Molteni L. E C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. Use of metformin in the preparation of pharmaceutical compositions capable of inhibiting the enzyme dipeptidyl peptidase iv
TWI249401B (en) 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
DK1173434T3 (da) 1999-04-23 2003-12-08 Smithkline Beecham Plc Thiazolidindionderivat og dets anvendelse som antidiabetisk middel
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
CA2389928C (en) 1999-11-03 2010-03-23 Bristol-Myers Squibb Company Method for treating diabetes
AU1403501A (en) * 1999-11-16 2001-05-30 Smithkline Beecham Plc Novel composition and use
MY125516A (en) * 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
US20010036479A1 (en) 2000-01-14 2001-11-01 Gillian Cave Glyburide composition
GB0006133D0 (en) 2000-03-14 2000-05-03 Smithkline Beecham Plc Novel pharmaceutical
CA2407713A1 (en) * 2000-05-01 2001-11-08 Aeropharm Technology, Inc. A core formulation
FR2812547B1 (fr) * 2000-08-04 2002-10-31 Lipha Composition pharmaceutique comprenant une association metformine et derive de thiazolidinedione et son utilisation pour la preparation de medicaments destines a traiter le diabete
CA2434169C (en) 2001-01-12 2011-03-15 Sun Pharmaceutical Industries Limited Spaced drug delivery system
FR2838968A1 (fr) * 2002-04-30 2003-10-31 Lipha Association d'insuline et d'un derive de thiazolidinedione et son utilisation pour traiter le diabete
WO2003105809A1 (en) 2002-06-17 2003-12-24 Themis Laboratories Private Limited Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them
CN101623274B (zh) * 2002-09-20 2012-06-27 华生制药公司 含有双胍和噻唑烷二酮衍生物的药物剂型
UA80991C2 (en) 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
CA2514539C (en) 2003-01-29 2012-03-06 Takeda Pharmaceutical Company Limited Process for producing coated preparation
WO2005099760A1 (ja) 2004-04-14 2005-10-27 Takeda Pharmaceutical Company Limited 固形製剤
CN1327840C (zh) * 2004-06-08 2007-07-25 天津药物研究院 一种药物组合物及其在制备用于治疗糖尿病中的应用
WO2006011397A1 (ja) * 2004-07-27 2006-02-02 Kowa Company., Ltd. 糖尿病の予防または治療のための薬剤
US20070032420A1 (en) * 2005-02-09 2007-02-08 Entelos, Inc. Treating diabetes with glucagon-like peptide-1 secretagogues
US20090137626A1 (en) * 2005-07-12 2009-05-28 Akira Okuno Pharmaceutical Composition Containing PPARgamma Agonist
DE06252444T8 (de) * 2006-05-09 2009-03-19 Teva Pharmaceutical Industries Ltd. 2-N-{5-[[4-[2-(Methyl-2-pyridinylamino)-ethoxy]-phenyl]-methyl]-2,4-thiazolidindion}-bernsteinsäure, Verfahren zur Herstellung und Zusammensetzungen mit Rosiglitazonmaleat
US7435741B2 (en) 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
CN101069745B (zh) * 2006-05-12 2010-07-21 北京华安佛医药研究中心有限公司 治疗2型糖尿病的药物组合物
US7919410B2 (en) * 2007-03-14 2011-04-05 Aptina Imaging Corporation Packaging methods for imager devices
CN102137836B (zh) * 2008-07-28 2015-08-26 赛丹思科大学 用于治疗代谢疾病的化合物
DE102009053562A1 (de) 2009-11-18 2011-05-19 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Rosiglitazonsuccinat enthaltende pharmazeutische Zusammensetzung
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
US9572784B2 (en) 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
US9480663B2 (en) 2011-01-07 2016-11-01 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
RS61153B1 (sr) 2011-01-07 2020-12-31 Anji Pharma Us Llc Ligand hemosenzornog receptora-osnovne terapije
NZ626578A (en) 2012-01-06 2016-11-25 Elcelyx Therapeutics Inc Compositions and methods for treating metabolic disorders
BR112014016808B1 (pt) 2012-01-06 2022-01-11 Anji Pharma (Us) Llc Uso de um composto de biguanida para a fabricação de um medicamento para baixar os níveis de glicose no sangue e para o tratamento de um distúrbio do metabolismo de glicose

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) * 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
CN1003445B (zh) * 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
JPH06779B2 (ja) * 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US4812570A (en) * 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
ATE186724T1 (de) * 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
US4895862A (en) * 1989-04-21 1990-01-23 American Home Products Corp. Novel benzyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents
US5068342A (en) * 1989-10-27 1991-11-26 American Home Products Corporation 5-[(1- and 2-naphthalenyl)thio and sulfonyl]-2,4-thiazolidinediones and derivatives thereof
WO1991007107A1 (en) * 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
JPH04210683A (ja) * 1990-12-06 1992-07-31 Terumo Corp チアゾリジン−２，４−ジオン誘導体およびこれを含有する糖尿病合併症治療薬
ES2101866T3 (es) * 1991-08-26 1997-07-16 Upjohn Co Producto alimentario liquido que contiene acido 3-guanidinopropionico.
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
MX9709874A (es) * 1995-06-06 1998-03-31 Pfizer N-(INDOL-2-CARBONIL) beta-ALANILAMIDAS SUSTITUIDAS Y DERIVADOS COMO INHIBIDORES DE GLUCOGENO FOSFORILASA, USO DE LOS MISMOS Y COMPOSICIONES QUE LOS CONTIENEN.
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
JPH09270635A (ja) * 1996-04-01 1997-10-14 Honda Motor Co Ltd 平面アンテナモジュール
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
US6291495B1 (en) * 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
US6153632A (en) * 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
US20020177612A1 (en) * 1997-06-05 2002-11-28 Smithkline Beecham P.I.C. Composition comprising 5-[4-[2-(N-methyl-N-2-pyridy)amino)ethoxy]benzyl]thiazolidine-2,4-dione
US20020016287A1 (en) * 1997-07-18 2002-02-07 Smithkline Beecham P.L.C. Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide
EP1039890B1 (en) * 1997-12-08 2004-03-17 Bristol-Myers Squibb Company Novel salts of metformin and method
EP1555845A1 (de) * 2004-01-15 2005-07-20 Siemens Aktiengesellschaft Verfahren zur Positionsbestimmung von Teilnehmerstationen eines Funkkommunikationssystems

Also Published As

Publication number Publication date
PL195140B1 (pl) 2007-08-31
WO1998057634A1 (en) 1998-12-23
NO324993B1 (no) 2008-01-14
NO326958B1 (no) 2009-03-23
PE83199A1 (es) 1999-10-22
TW565449B (en) 2003-12-11
KR20010013844A (ko) 2001-02-26
CZ298469B6 (cs) 2007-10-10
BG104060A (en) 2000-10-31
ATE355840T1 (de) 2007-03-15
KR20060105005A (ko) 2006-10-09
TR199903057T2 (xx) 2000-04-21
CA2294582A1 (en) 1998-12-23
US20070004780A1 (en) 2007-01-04
NL300288I2 (nl) 2009-06-02
LU91356I2 (fr) 2008-01-29
US20080090881A1 (en) 2008-04-17
ES2284212T3 (es) 2007-11-01
CN1260716A (zh) 2000-07-19
NO20063000L (no) 1999-12-17
PT996444E (pt) 2007-06-08
NO996266D0 (no) 1999-12-17
BG64818B1 (bg) 2006-05-31
NO20090846L (no) 1999-12-17
BG109398A (bg) 2006-05-31
AR012998A1 (es) 2000-11-22
ID23372A (id) 2000-04-20
EP1787646A2 (en) 2007-05-23
AP9901719A0 (en) 1999-12-31
IN189722B (en:Method) 2003-04-19
NO2008003I1 (no) 2008-04-21
OA11516A (en) 2004-02-04
IL173650A0 (en) 2006-07-05
MY129897A (en) 2007-05-31
JP2002504137A (ja) 2002-02-05
HK1028193A1 (en) 2001-02-09
SK286029B6 (sk) 2008-01-07
CZ9904578A3 (en) 2001-06-13
EA200000041A1 (ru) 2000-08-28
CY2007018I1 (el) 2012-01-25
BR9810172A (pt) 2000-08-08
EP0996444B1 (en) 2007-03-07
CY1107643T1 (el) 2012-01-25
EA003144B1 (ru) 2003-02-27
PL337362A1 (en) 2000-08-14
IL133142A (en) 2006-06-11
IL133142A0 (en) 2001-03-19
US20060100247A1 (en) 2006-05-11
DE69837261T2 (de) 2007-11-08
DZ2520A1 (fr) 2003-02-01
AR012995A1 (es) 2000-11-22
CN1429551A (zh) 2003-07-16
MA26512A1 (fr) 2004-12-20
SK179299A3 (en) 2000-11-07
CN1230171C (zh) 2005-12-07
PL195136B1 (pl) 2007-08-31
DE122007000054I1 (de) 2007-12-13
NZ501260A (en) 2002-09-27
NO996266L (no) 1999-12-17
NO2008003I2 (no) 2010-06-28
EP1787646A3 (en) 2007-10-03
AU8539398A (en) 1999-01-04
NL300288I1 (nl) 2007-11-01
AP1279A (en) 2004-05-20
DE69837261D1 (de) 2007-04-19
UY25049A1 (es) 2000-09-29
SI0996444T1 (sl) 2007-08-31
CN1114404C (zh) 2003-07-16
KR100666591B1 (ko) 2007-01-11
CA2294582C (en) 2008-02-12
EP0996444A1 (en) 2000-05-03

Similar Documents

Publication Publication Date Title
DK0996444T3 (da) Behandling af diabetes med thiazolidindion og metformin
DK1174135T3 (da) Farmaceutisk sammensætning omfattende pioglitazon og glimepirid til anvendelse i behandling af diabetes
DK1183020T3 (da) (3-trihalogenmethylphenoxy)(4-halogenphenyl) til behandling af insulinresistens og type 2-diabetes
NO954239D0 (no) Heterocykliske forbindelser og deres fremstilling og anvendelse
FI964314A7 (fi) Substituoidut sulfonamidit selektiivisinä beta3-agonisteina diabeteksen ja liikalihavuuden hoitoon
DK0445255T3 (da) Behandling af tilstande og sygdom
DK1228067T3 (da) 5-leddede heterocykliske forbindelser med hypoglykæmisk og hypolipidæmisk virkning
PT1017408E (pt) Utilizacao de tetra-hidrolipstatina no tratamento de diabetes de tipo ii
DK1001783T3 (da) Behandling af diabetes med thiazolidindion, insulinsekretagog og biguanid
NO996265D0 (no) Behandling av diabetes med rosiglitazon og insulin
DK0998291T4 (da) Behandling af diabetes med thiazolidindion og sulphonylurinstof
NO984578L (no) Piezoelektrisk resonator og komponent med samme
NO996264L (no) Behandling av diabetes med tiazolidindion og sulfonylurea
NO20000230D0 (no) Behandling av diabetes med tiazolidindion, insulin sekretagogue og <alfa>glukosidaseinhibitor
NO996270D0 (no) Behandling av diabetes med tiazolidindion og <alfa>- glukosidaseinhibitor
HUP0002668A3 (en) Treatment of diabetes with thiazolidinedione and metformin
HUP0002669A3 (en) Treatment of diabetes with thiazolidinedione and sulphonylurea